Evidence map›Paper›PMID 41732388›Full record

ArticleMaterials today. Bio2026

Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy.

Maojin Tian, Xiangwei Meng, Weiwei Song, Zhengyu Wu, Yang Liu, Xianing Dong, Shuai Ren, Juan Du, Peiqing Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maojin TianDepartment of Critical Care Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
Xiangwei MengDepartment of Drug Clinical Trials, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
Weiwei SongDepartment of Critical Care Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
Zhengyu WuResearch Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Yang LiuCenter of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
Xianing DongCenter of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
Shuai RenCenter of Translational Medicine, Department of Oncology, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
Juan DuDepartment of Immunology, College of Basic Medicine, Guilin Medical University, Guilin, 541199, China.
Peiqing ZhaoCenter of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is among the most lethal biliary malignancies because it is often diagnosed at an advanced stage, displays a highly desmoplastic tumor microenvironment, and shows intrinsic resistance to gemcitabine (GEM)-based chemotherapy. Fibronectin 1 (FN1), a major extracellular matrix component, is markedly upregulated in GBC and contributes to chemoresistance through activation of the PI3K/AKT signaling pathway. Tumor-penetrating iRGD-modified PEG-PLGA nanoparticles (iRGD-NPs) were engineered to encapsulate FN1 small interfering RNA (siRNA) for targeted stromal modulation. iRGD-NPs improved tumor penetration and enabled efficient intracellular delivery of siRNA

Indexed as

Fibronectin-1Gallbladder cancerGemcitabine resistanceiRGD nanoparticlesPI3K/AKT signalingTumor microenvironment

Identifiers

PMID41732388
PMCPMC12925212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.